Literature DB >> 2899517

Entamoeba histolytica: virulence potential and sensitivity to metronidazole and emetine of four isolates possessing nonpathogenic zymodemes.

G D Burchard1, D Mirelman.   

Abstract

The pathogenic potential of four Entamoeba histolytica isolates obtained from asymptomatic carriers and possessing nonpathogenic zymodemes was compared to four E. histolytica strains obtained from invasive cases of amebiasis and having pathogenic zymodemes. Both xenic and axenic cultures of a number of strains were tested. Determinations of cytopathogenicity were done in vitro by measuring the rates of destruction of tissue cultured monolayers of baby hamster kidney cells by intact amebae or by its cell-free extracts. The in vivo virulence was tested by assessing their capacity to form hepatic abscesses in hamsters or cecal ulcerations in rats. The results obtained show that two of the isolates from asymptomatic carriers (strains SAW 1734R clAR and WI:0385:191) were as virulent as three of the invasive ones (HM-1:IMSS, 200:NIH, and SAW 408). Two other isolates from asymptomatic carriers and one from a dysentery case were avirulent. All the E. histolytica isolates tested were similarly sensitive to metronidazole and emetine (IC50 1-10 micrograms/ml). The results indicate that the pathogenic potential of E. histolytica varies between isolates and can be affected by culture conditions and by the presence or absence of bacterial cells. These findings suggest that virulence does not necessarily correlate with a pathogenic zymodeme.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2899517     DOI: 10.1016/0014-4894(88)90095-1

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  10 in total

1.  Drug susceptibility testing of anaerobic protozoa.

Authors:  J A Upcroft; P Upcroft
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  In Vitro Testing of Potential Entamoeba histolytica Pyruvate Phosphate Dikinase Inhibitors.

Authors:  Syazwan Saidin; Nurulhasanah Othman; Rahmah Noordin
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

3.  Antigens in electron-dense granules from Entamoeba histolytica as possible markers for pathogenicity.

Authors:  M L Muñoz; E Lamoyi; G León; R Tovar; J Pérez-García; M De La Torre; E Murueta; R M Bernal
Journal:  J Clin Microbiol       Date:  1990-11       Impact factor: 5.948

4.  Pathogenic and nonpathogenic strains of Entamoeba histolytica can be differentiated by monoclonal antibodies to the galactose-specific adherence lectin.

Authors:  W A Petri; T F Jackson; V Gathiram; K Kress; L D Saffer; T L Snodgrass; M D Chapman; Z Keren; D Mirelman
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

5.  Characterization of 20 Entamoeba histolytica strains isolated from patients with HIV infection.

Authors:  G D Burchard; F T Hufert; D Mirelman
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

6.  Susceptibility of an emetine-resistant mutant of Entamoeba histolytica to multiple drugs and to channel blockers.

Authors:  J C Samuelson; A Burke; J M Courval
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

7.  Adherence of pathogenic and non-pathogenic Entamoeba histolytica strains to neutrophils.

Authors:  G D Burchard; R Bilke
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

8.  Specific labeling of cysteine proteinases in pathogenic and nonpathogenic Entamoeba histolytica.

Authors:  F de Meester; E Shaw; H Scholze; T Stolarsky; D Mirelman
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

Review 9.  Host-Parasite interactions in Entamoeba histolytica and Entamoeba dispar: what have we learned from their genomes?

Authors:  I W Wilson; G D Weedall; N Hall
Journal:  Parasite Immunol       Date:  2012 Feb-Mar       Impact factor: 2.280

10.  In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar.

Authors:  Devendra Bansal; Rakesh Sehgal; Yogesh Chawla; Ramesh Chander Mahajan; Nancy Malla
Journal:  Ann Clin Microbiol Antimicrob       Date:  2004-12-21       Impact factor: 3.944

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.